The data, released following the latest meeting of the European regulator’s Pharmacovigilance Risk Assessment Committee (PRAC), backed up previous concerns about the potential risk posed by the Covid vaccines.
Both myocarditis and pericarditis are deemed “very rare” in recipients of the Comirnaty jab, produced by Pfizer-BioNTech, and Spikevax, previously known as the Moderna vaccine.